|Date:||September 18, (Wed.) 2019 16:00~|
|Room:||Seminar Room, 1st floor, Bldg. #2 of Institute for Frontier Life and Medical Sciences ,Kyoto University|
|Speaker:||Dr. Sumin Kang
Associate Professor, Winship Cancer Institute
Department of Hematology and Medical Oncology
Emory University School of Medicine
|Title:||Targeting cancer signaling nodes to overcome metastasis
and chemotherapy resistance
Metastatic or therapy resistant cancers are often considered incurable. Although dysregulated metabolism and kinase signaling have been demonstrated in cancer cells, the precise mechanism remains unclear. We performed transcriptomics screen and identified GDH1 as a critical metabolic factor which provides anti-anoikis and pro-metastatic signals through activating CamKK2 and AMPK that promotes tumor metastasis in lung cancer. Targeting GDH1 with a GDH specific inhibitor R162 attenuated tumor metastasis in mice. We also performed cisplatin synthetic lethal partner screen using kinome shRNA library and identified MAST1 as a promising target to overcome cisplatin resistance. Mechanistically, we demonstrated that cisplatin dissociates cRaf from MEK1 to inhibit the MAPK pathway and identify MAST1 as a main cisplatin resistance driver that replaces cRaf to reactivate the MAPK pathway. Through a drug repurposing study, lestaurtinib was identified as a MAST1 inhibitor. Lestaurtinib effectively inhibits MAST1 kinase activity and cancer cell proliferation in combination with platinum-based compounds including cisplatin and carboplatin.
Biography: Dr.Kang’s research has focused on how intricate molecular communication networks evolve to control cell growth, survival, and proliferation in cells, and how disruption of these processes leads to cancer, with a particular focus on the role of cellular protein kinase signaling and metabolic reprogramming in tumorigenesis, tumor metastasis, and chemotherapy resistance in human cancers. In addition, her group evaluates the novel therapeutic targets by developing and characterizing specific small molecule inhibitors in preclinical treatment of human cancers. The research findings have been published in journals including Cancer Cell, Nat Cell Biol, Mol Cell, J Clin Invest, and Oncogene. Dr. Kang is supported with prestigious awards from NIH, Department of Defense, American Cancer Society, and Leukemia & Lymphoma Society.
（ Language : English）
|Invitator||Lab. of Cell Fate Dynamics and Therapeutics|
|Takahiro Ito Tel 075 -751-4809|